Overview:
Prostate cancer remains a major clinical challenge, particularly in advanced stages where treatment decisions are increasingly complex. PSMA-targeted imaging and radioligand therapies offer new opportunities to improve outcomes, but gaps remain in clinician understanding of patient selection, treatment sequencing, and multidisciplinary coordination.
This 2-hour hybrid tumor board symposium will be held during the 2025 ASTRO Annual Meeting in San Francisco, CA. Through expert-led case discussions and interactive audience participation, the program will address key decision points in integrating PSMA imaging and targeted therapies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Explain the diagnostic and prognostic significance of PSMA PET/CT in prostate cancer and interpret imaging findings to guide radiotherapy planning and clinical decision-making.
- Assess recent clinical evidence for PSMA-targeted radioligand therapies and define the role of radiation oncology in their delivery, monitoring, and coordination.
- Design patient-centered strategies for incorporating PSMA-directed radioligand therapy into care pathways, including sequencing and coordination with other specialties.
- Identify institutional and logistical barriers to radioligand therapy delivery and propose solutions to expand access.
Ana Kiess, MD, PhD
Associate Professor
Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins School of Medicine
Baltimore, MD
Himanshu Nagar, MD, MS
Director of Genitourinary Cancers
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Scott T. Tagawa, MD, MS, FASCO, FACP
Professor of Medicine & Urology
Weill Cornell Medicine
Meyer Cancer Center
New York, NY
Erin Grady, MD, CCD, FACNM, FSNMMI
Nuclear Medicine and Molecular Imaging Interim Division Chief
Associate Chair of Education and Diversity, Equity & Inclusion
Clinical Professor, Department of Radiology
Stanford University
Palo Alto, CA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Medical Oncologists (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is supported by educational grants from Blue Earth Diagnostics; Lantheus; and Novartis Pharmaceuticals Corporation.
PER is proud to partner with ZERO Prostate Cancer.
